hit tracker
prime news list

all information about tech and other

Looking at rare allergic reactions to NIH COVID vaccines

Looking at rare allergic reactions to NIH COVID vaccines

By Steven Reinberg
HealthDay Reporter

THURSDAY, APRIL 8, 2021 (HealthDay News) – new clinical trial will investigate whether those who are very allergic or know about mast cell disorder are suddenly at higher risk allergic reaction Modern or Pfizer to COVID-19 vaccines.

“It is understandable that people are reporting rare and serious allergic reactions to Modern and Pfizer-BioNTech COVID-19 vaccines,” said Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

“The information gathered in this trial will provide doctors with information about the risks and benefits of receiving both vaccines for people with severe allergies or mast cells. However, for most people the benefits of the COVID-19 vaccine outweigh the risks,” Fauci told NIAID news. in a.

A systemic allergic reaction to the vaccine occurs in one or more parts of the body that are far from the injection site.

Masculine imbalance is caused by a type of white blood cell that is abnormal, overactive, or both. It puts a person at risk for life in the form of allergic reactions.


Researchers will also examine the biological mechanism that causes the reactions and whether there is a way to predict whether it is at greatest risk.

Modern and Pfizer COVID-19 vaccines have been given to millions of Americans. Most serious and rare reactions have occurred in people with a history of allergies. Some of them had an life-threatening allergic reaction before anaphylaxis, the researchers noted.

The new study will enroll 3,400 people between the ages of 18 and 69. According to NIAID, 35 allergy research centers in the United States will participate.

According to the design, about 60% of the study participants must have a history of severe allergic reactions or have been diagnosed with a mast cell disorder. The rest don’t.

Participants will be randomly assigned a Pfizer or Moderna shot or placebo then both vaccines.

About two-thirds of the participants will be women because severe allergic reactions to vaccines – and especially Moderna and Pfizer COVID-19 vaccines – have occurred in women, the researchers said.


The researchers will examine how many participants in each group have a systemic allergic reaction within 90 minutes of injection.

Results are expected by the end of the summer.

More information

To learn more about the safety of the COVID-19 vaccine, visit U.S. Centers for Disease Control and Prevention.

SOURCE: US National Institute of Allergy and Infectious Diseases, news, April 7, 2021

Source link


Leave a Reply

Your email address will not be published. Required fields are marked *